Mirabegron Glenmark (Mirabegron)

The drug activates β3‑adrenergic receptors on the bladder’s smooth‑muscle cells. This activation raises cyclic AMP levels, leading to muscle relaxation during the storage phase, which expands functional bladder capacity and diminishes involuntary contractions that cause urgency.

The appropriate dose is determined by the prescribing clinician based on the patient’s condition, renal function, and blood‑pressure status. Dosage adjustments may be required for specific populations, and the prescriber will provide individualized instructions.

Safety data for Mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Unlike antimuscarinics, which block muscarinic receptors, Mirabegron stimulates β3‑adrenergic receptors, offering a different mechanism that may result in fewer dry‑mouth and constipation side effects. Choice of therapy depends on patient tolerance, comorbidities and physician judgment.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Mirabegron Glenmark is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious adverse events can include significant hypertension, urinary retention, tachyarrhythmias, angioedema, and rare cases of myocardial infarction. Patients should be monitored for these conditions, and therapy should be discontinued if they occur.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe urinary retention, or known hypersensitivity to the drug. Caution is also advised for individuals with significant cardiovascular disease, severe renal impairment, or those taking strong CYP2D6 inhibitors.